[1] Sablina AA,Hector M,Colpaert N,et al. Identification of PP2A complexes and pathways involved in cell transformation[J]. Cancer Res,2010,70(24):10474-10484. [2] Murata K,Wu J,Brautigan DL. B cell receptor-associated protein alpha4 displays rapamycin- sensitive binding directly to the catalytic subunit of protein phosphatase 2A[J]. Proc Natl Acad Sci USA,1997,94(20):10624-10629. [3] Kong M,Ditsworth D,Lindsten T,et al. Alpha4 is an essential regulator of PP2A phosphatase activity[J]. Mol Cell, 2009,36(1):51-60. [4] Zabrocki P,Van Hoof C,Goris J,et al. Protein phosphatase 2A on track for nutrient-induced signalling in yeast[J]. Mol Microbiol,2002,43(4):835-842. [5] Kong M,Fox CJ,Mu J,et al. The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis[J]. Science,2004, 306(5696):695-698. [6] Kong M,Bui TV,Ditsworth D,et al. The PP2A-associated protein alpha4 plays a critical role in the regulation of cell spreading and migration[J]. J Biol Chem,2007,282(40): 29712-29720. [7] Pang Y,Li W,Ma R,et al. Development of human cell models for assessing the carcinogenic potential of chemicals[J]. Toxicol Appl Pharmacol,2008,232(3):478-486. [8] Ji W,Yang L,Yu L,et al. Epigenetic silencing of O6-methylguanine DNA methyltransferase gene in NiS-transformed cells[J]. Carcinogenesis,2008,29(6):1267-1275. [9] Irigaray P,Belpomme D. Basic properties and molecular mechanisms of exogenous chemical carcinogens[J]. Carcinogenesis, 2010,31(2):135-148. [10] Westermarck J,Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation[J]. Trends Mol Med, 2008,14(4):152-160. [11] Sakashita S,Li D,Nashima N,et al. Overexpression of immunoglobulin (CD79a) binding protein1 (IGBP-1) in small lung adenocarcinomas and its clinicopathological significance[J]. Pathol Int,2011,61(3):130-137. [12] Wullschleger S,Loewith R,Hall MN. TOR signaling in growth and metabolism[J]. Cell,2006,124(3):471-484. [13] Yamashita T,Inui S,Maeda K,et al. The heterodimer of alpha4 and PP2Ac is associated with S6 kinase1 in B cells[J]. Biochem Biophys Res Commun,2005,330(2):439-445. [14] Conde E,Angulo B,Tang M,et al. Molecular context of the EGFR mutations:evidence for the activation of mTOR/S6K signaling[J]. Clin Cancer Res,2006,12(3 Pt 1):710-717. [15] Bjornsti MA,Houghton PJ. The TOR pathway:a target for cancer therapy[J]. Nat Rev Cancer,2004,4(5):335-348. |